Table 1. Demographics, concomitant ocular and systemic diseases, and medications at initial evaluation.
| Sex | ||
| Female | 12 | 80% |
| Male | 3 | 20% |
| Age (mean) | 68.27 years | ±14.35 |
| Previous diagnosis of pemphigus vulgaris | 1 | 6.7% |
| Concomitant systemic diseases | ||
| Systemic arterial hypertension | 9 | 60% |
| Diabetes mellitus | 3 | 20% |
| Hypothyroidism | 1 | 6.7% |
| Hyperthyroidism | 1 | 6.7% |
| Sjögren's syndrome | 2 | 13.3% |
| Rheumatoid arthritis | 1 | 6.7% |
| Asthma | 1 | 6.7% |
| Systemic medications | ||
| ACE inhibitors | 4 | 26.7% |
| Beta-blockers | 3 | 20% |
| Glibenclamide | 3 | 20% |
| Angiotensin II receptor blockers | 1 | 6.7% |
| NSAIDs | 1 | 6.7% |
| Methimazole | 1 | 6.7% |
| Concomitant ocular diseasesa | ||
| Cataract | 6 | 20% |
| Glaucoma | 6 | 20% |
| Age-related macular degeneration | 4 | 13.3% |
| Previous ocular surgerya | ||
| Extracapsular-cataract extraction (ECCE) | 6 | 20% |
| Trabeculectomy | 4 | 13% |
| Pterygium resection | 3 | 10% |
| Topical medicationa | ||
| NSAIDs | 2 | 6.7% |
| Beta-blockers | 3 | 10% |
| Carbonic anhydrase inhibitors | 5 | 16.7% |
| Prostaglandin analog | 3 | 10% |
a
Number of eyes was considered.